| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
14-May-2008 09:31
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Forumer Cellar_door: they should employ you for PR. Btw, can explain the instituional investors' lack of interest in this stock? You look at how BIG is doing their investor relations you think institutions will be interested? Immediately after CE they give net profit forecast of breakeven for FY2009. It is plain stupidity and a very lousy self-destruction forecast. All the analysts will just blindly follow this silly net profit forecast and also write some numbers in accordance to what BIG said. When institutional clients see such reports also no mood to put money into BIG. It all boils down to good investor PR. You think the analysts bother to do deep analysis into BIG like Mr Ang Tay Kor here? You guys will find out more about BIG in my forum thread as compared to reading some inconsequential analyst reports with little or no meaning, crunch some numbers and give you net profit forecast for FY2009 is "zero". I think portfolio funds here rarely invest in biotech/biomed stocks. Only in USA or Europe got such specialised funds. Normally each fund has got a "theme". Biomed is not well covered in any theme or sector for funds in Singapore. This is just my guess because Im not the institutional player so its hard for me to comment. But all it takes is for BIG to announce one more profit related good news and im pretty sure this counter will be on the radar screen of institutional investors again. Got to erase away that stupid breakeven net profit for FY2009 thing. That is one of the dumbest thing i have ever heard from BIG's management. Anybody/ any investor hear already also dump or avoid lah. Most people will think i better not buy this stock until next year when this company start making money. Even until now people still think BIG is a concept stock and stuck with losses year after year. I feel with BIG's business model, BIG has multiple streams of potential income (which is very difficult to quantify) that a lot of investors missed out this potential. Now BIG start making money liao but very few believe BIG will big bucks anytime soon yet. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
14-May-2008 09:28
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Forumer Tankuku: when i said that this stk cannot move.... it does not mean that fundamentally this company is not good........ I believe this stk would do much better, had it listed elsewhere earlier where the mkt can appreciate its value........ Listed locally here, you can tell that over time, this stk is really not performing....... A secondary listing probably in NASDAQ would surely increase this darling's PR & $$ value to all shareholders........... Yes, this stock should be listed in USA instead of in SGX. But who ask LYC to listen to someone's advice to list it here in Singapore and to promote knowledge-based economy (clue: the most powerful old man in Singapore). Very bad move for BIG to list in Singapore. Also, BIG used to have an fairly good external PR company doing the PR but i heard their contract kena terminated becos buay guam with BIG's PR dept. After the BBs involved in IPO pump it to $1.50, they sold off most of their shares. Some pre-IPO investors also sold off huge chunks. Now we have a free float that is too large and i believe price movement done by the so called BBs now are mostly brokerage house traders. But don't worry, there is a Germany based European group who is very shocked at the low valuation of BIG and taking a very serious look at this company. I heard they are doing due-D now and has intention to hold a very significant stake in BIG. When the Germans first looked at BIG, they said China JWMS is actually worth US$0.8 to 1B and takeover valuation of BIG should be at least US$2.5B. They also know that BIG's licensing will reduce takeover valuation of BIG as BIG's DES technology will becomes less exclusive. Hope some institutional investors will realise BIG's real potential and mop up some free float. Bo Li You fundamentals improve so much but share price still stuck at 70ct. That is why im here in forums explain to investors the fundamentals of BIG. If BIG do kena takeover by medical device MNC, you can be rest assure no other knowledge based biotech/biomed company will ever be listed in Singapore. BIG will be the last one here in SGX. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
allright
Senior |
14-May-2008 09:27
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
I meant, I hope the analyst gets to read our forummers' research. This brave call by piper Jaffray is relevant to Biosensors but no one seems exceited in Singapore..... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
14-May-2008 09:25
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
10 things to know about Biosensors now: 1. Undisputed global number one in clinical trial results beating rivals by very wide margins in all end-point measurements 2. Holding the most important DES industry patent "any limus drug on biodegradable polymer". Many DES rivals are in breach of this key patent and that means potential future patent income. Settlement package for each and every such patent breach will be lum sum payment of at least US$100m cash plus 10% royalty from future sales. 3. China JWMS subsidiary made US$16m last year, will make at least US$25m this year and US$40m next year. I am only talking about their domestic China market sales excluding their export market sales potential. China JWMS will be a wholly owned subsidiary of Biosensors and a listing of China JWMS in 2009 will value this subsidiary easily at US$800m (20 times forward PE of 2009 earnings). 4. CE approval for flagship product Biomatrix. Biomatrix is the only CE approved biodegradable polymer DES in the world now. 5. Just received US$40m cash profit from licensee 6. Potential additional profits from licensing agreements 7. Has US$100m cash in bank now 8. All of Biosensors's DES technology are 100% proprietary, no borrowing of technology 9. Revolutionary "Biodegradable polymer" addresses blood-clot problems faced by currently available DESs. BIG is the pioneer and leader in this biodegradable polymer field in DES. 10. One and only worthwhile takeover target in the DES industry. Number one potential buyer: Johnson & Johnson (very very cash rich and also very very desperate now) I have to admit the PR of this company is no good and the guy in charge is an ex-civil service officer, not like some other flamboyant Ang Moh PR professional. That is why i ownself volunteer to do internet PR for Biosensors FOC. BIG is stupid to talk nonsense immediately after CE approval and make investors think that BIG will lose money in H1 and breakeven or make small money in H2 of FY2009 (which implies that BIG will probably just breakeven at best for the whole of FY2009). When you make such silly low forecast, you will turn off current and potential investors. Even the analysts will just take que from BIG's own forecast and give a zero net profit forecast also. Institutional funds will be turned off by such forecast. I seriously think BIG's FY2009 net profit forecast will be way off-track. Also, they could have booked the US$40m cash received in full as Q1 FY2009 net profit. No one can fault them since the money already in their bank account and don't have to recognise it over 5 years. With US$40m profit and earnings of China JWMS, this company is already a single digit PE company. I believe there will be more profits rolling in after BIG's CE approval. The US$40m cash profit is made possible because of CE approval. I always remind investors to look at the business model of BIG very carefully to have a better gauge of what other kind of income streams may be coming in. You will be shocked at what kind of multi-million dollars deals and profit BIG can bring in. If you are still stuck at the belief that this counter is just a concept stock, ask yourself one simple question: Will a concept stock company be able to make US$40m cash profit? I will do the conversion for you...... its S$55,000,000.00 CASH!!!!! Hian Lwee Bo Pang Siao. Not some revaluation profit or profit figures still stuck in some Tankuku accounts receivable. The money is Sio Sio in BIG's bank account. I can see more multi-million streams of income coming in soon for this company. Ask yourself how did BIG make this US$40m cash profit suddenly? Im talking about Biomatrix DES only. USA market licensing deal is not awarded yet. According to BIG's US$40m announcement, CE markets for licensee duration last only 5 years. Ask yourself is 5 years enough for licensees? Aren't the licensees afraid BIG kena takeover and end of licensing after 5 years? Biomatrix has a product life of a good 10 years. What about other licensees like Xtent and Devax who will be getting their CE in a few months time? This stock looks like a PE of 4 times to me at current prices. BIG still has next generation DES Biomatrix-Freedom and 100% biodegradable polymer DES not licensed out yet. I also believe in 2009, Abbott will get their CE Mark for ABSORB DES. This DES breaches BIG's patent "limus drug on biodegradable polymer". Abbott will have to seek patent breach waiver from BIG and i estimate the deal should be worth US$100m cash upfront settlement plus 10% royal of future sales of ABSORB DES. There are easily 5 other next generation DES in breach of BIG's patent. You ownself go and calculate how much these patent settlement package will be worth eventually. If they don't settle patent breach with BIG, BIG will institute worldwide sales injunction and bring them down on their knees. Companies like BIG (if remain independent) can Kiow Kar Yeoh Lum Par in future also got at least US$100m cash royalties rolling in every year. This is how small but technologically very advanced biomed companies like BIG make money on global markets. So many investors still cannot see this future source of income and potential. Its the IPs and patents, get it!!!??? |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
allright
Senior |
14-May-2008 09:19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Yes they probably don't understand half as much as you guys although some like the Deutsch guy is not bad.....The inability to see the potential and to call a brave buy by our local analyst...That has been our grouse all the time. Let's hope the analysts get hope of our esteemed forummers research in the postings..... |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
14-May-2008 09:13
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Analysts here is not skilled or bold enough to write valuations of BIG. Nobody dare to write that takeover premium of BIG can be 100% above their TP. But in actual fact 100% takeover premium are common for biotechs in USA and judging from how the investors here are valuing BIG despite of what BIG has achieved, i can safely say takeover premium will be 100% or more. This company at US$550m market cap valuation now is ridiculous. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PensionAlterEgo
Member |
14-May-2008 09:00
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Piper Jaffray added XTENT, Inc. (Nasdaq: XTNT) to their Alpha List, maintaining their Buy rating and $10 price target. The firm said they expect the EuroPCR meeting to generate excitement for XTNT's Custom NX drug eluting stent. The company will present data from the 6-month follow-up results of the CUSTOM III clinical trial on Tuesday, May 13. The firm expects that positive news flow and positive chatter will move XTNT's stock price notably higher. The firm's $10 price target represents a 170% gain from the current stock price. What a contrast compared to Singapore.. ! In US, analyst puts target prices at 170% just for positive resutls in 6-months trials..... but in Singapore (for BIG), its maybe 17%! Should really do a double listing in Nasdaq! |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
14-May-2008 00:01
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting Tuesday May 13, 11:40 am ET BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT - News) today announced positive six-month follow-up data from the CUSTOM III clinical trial, which assessed the safety and efficacy of the Custom NX® drug eluting stent (DES) system for the treatment of patients with coronary artery disease.The CUSTOM III clinical trial was a 90-patient prospective study to assess the safety and efficacy of the Custom NX drug eluting stent system in patients with up to two de novo lesions treatable with up to 60 mm of customizable stent length. The primary endpoint was major adverse cardiac events (MACE) at 30 days, with secondary endpoints of MACE at six months, binary restenosis, late loss, and stent thrombosis.
CUSTOM III enrolled a challenging patient population, with 67 percent of the lesions classified as complex B2/C, an average lesion length of 19.8 mm, and an average reference vessel diameter (RVD) of 2.6 mm. The CUSTOM III trial included some of the longest lesion lengths and smallest RVDs compared to previous drug eluting stent trials. Lesion length and RVD are two important indicators of disease complexity. For the primary endpoint, MACE at 30 days, the rate was 2.2 percent, consisting of two in-hospital non Q-wave myocardial infarctions (MIs). At six-month follow-up the MACE rate for CUSTOM III was 7.8 percent. There were zero deaths, zero Q-wave MIs, two non Q-wave MIs, or 2.2 percent, and five clinically driven target lesion revascularizations, or 5.6 percent. There was one case of early stent thrombosis in the trial and zero late stent thrombosis. The in-stent late loss for CUSTOM III at six-month follow-up was 0.17 mm, the in-stent binary restenosis rate was 4.4 percent, and the neointimal hyperplasia (NIH) volume was 3.8 percent. "The CUSTOM III results are very promising and demonstrate the safety of in situ customization for treatment of simple and complex lesions. The IVUS and angiographic results confirm the efficacy of the Custom NX stent, and the Biolimus A9® and PLA formulation," said Bernard De Bruyne, M.D., Ph.D., of the OLV Clinic in Aalst, Belgium, and Principal Investigator for the CUSTOM III clinical trial. "Given the complexity of the patient population from CUSTOM III, we are excited about the results, which are consistent with the outcomes observed from the CUSTOM I and CUSTOM II trials," said Gregory D. Casciaro, XTENT's President and CEO. "We continue to be pleased with the safety profile and efficacy data of Custom NX in today's real-world patients." About the Custom NX® DES System Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6 mm cobalt chromium segments coated with Biolimus A9® and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6 mm segment and allows for the placement of up to 60 mm of stent. The Custom NX DES System has not been approved for sale by any regulatory authority. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
13-May-2008 23:48
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
UPDATE 2-Abbott stent tops rival Taxus at two years - study
NEW YORK, May 13 (Reuters) - Patients who received Abbott Laboratories' (ABT.N: Quote, Profile, Research) drug-eluting stent had significantly fewer heart attacks and other major adverse events after two years than patients receiving a top-selling Boston Scientific Corp (BSX.N: Quote, Profile, Research) stent, according a data presented on Tuesday. Abbott shares rose more than 3 percent and Boston Scientific shares were down 3 percent. While Abbott's experimental Xience V stent achieved a goal of non-inferiority to Boston Scientific's Taxus stent after one year in the study, it was clearly superior at two years, the trial's lead researcher said. "Between one and two years the safety and efficacy seemed to be spreading between the two stents, and while the differences were impressive at one year, they're even more impressive at two years," Dr. Gregg Stone, professor of medicine at Columbia University Medical Center, said in an interview. After two years, patients who received Xience stents had 45 percent fewer major cardiac events -- defined as heart attacks, cardiac death and need for repeat procedures due to blood vessel reclogging -- than Taxus patients, according to data presented at a medical conference in Barcelona. In the 1,002-patient study, sponsored by Abbott, 7.3 percent of Xience patients experienced a major cardiac event, compared with 12.8 percent of Taxus patients, researchers said. Abbott expects Xience to be approved for sale in the United States during the current quarter. This continuing five-year study is likely to help it grab significant market share. "The result reaffirmed the superiority of Xience," Wachovia analyst Larry Biegelsen said in a research note. He said the data were more impressive than those seen in an earlier Xience study "and reinforces our view that Xience will ultimately become the workhorse stent of choice." Stents are tiny wire mesh tubes used to prop open coronary arteries that have been cleared of blockages. Drug-releasing versions are designed to help prevent vessels from reclogging. The lucrative market has been dominated by Taxus and Johnson & Johnson's (JNJ.N: Quote, Profile, Research) Cypher. Medtronic Inc's (MDT.N: Quote, Profile, Research) drug-coated Endeavor joined the fray this year after winning U.S. approval in February. Abbott released one-year results from the study last year, but physicians and health regulators are extremely interested in longer-term data amid concerns about potentially deadly blood clots developing long after stents are implanted. These concerns have led to reduced use of the drug-coated devices and to patients staying on the blood clot preventer Plavix for six months or longer after receiving a stent. "I do think this will restore some confidence and I think that this will be very reassuring, that we now have a second-generation stent which almost cuts the overall adverse events rate from drug-eluting stents in half," Stone said. The biggest difference between the one-year and two-year data was the higher number of heart attacks seen in Taxus patients, Stone said. At two years, 5.6 percent of Taxus patients had had a heart attack, compared with 3.2 percent of Xience patients. Xience proved superior on other measures in the study as well. At two years, there was a statistically significant 32 percent reduction in target vessel failure with Xience compared to Taxus (10.7 percent vs 15.4 percent) -- a clear improvement over non-inferiority at one year. Target vessel failure is a reclogging anywhere in the treated blood vessel, not just at the site of the stent. Xience showed a 40 percent reduction in target lesion revascularizations -- the need for repeat procedures due to a reclogging of the stented area: 4.6 percent versus 7.5 percent for Taxus. Over the course of the second year, the rate of stent thrombosis, or development of blood clots, was low for both -- 0.3 percent for Xience and 1.0 percent for Taxus. There was a strong trend toward fewer blood clots developing in Xience patients who discontinued Plavix after six months: 0.4 percent compared to 2.6 percent with Taxus. That did not reach statistical significance and so cannot be chalked up as a proven benefit. "But its a six-fold difference, which if confirmed with longer-term follow-up or larger studies, which we're doing, it's potentially a very important difference," Stone said. "It's hard to ignore 2.6 percent versus 0.4 percent." Abbott shares were up $1.85, or 3.5 percent, to $54.63 in morning trade on the New York Stock Exchange, while Boston Scientific shares were off 42 cents, or 3.1 percent, to $12.99, also on the NYSE. (Editing by John Wallace) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
clauswu
Member |
13-May-2008 22:49
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
BOSTON (MarketWatch) -- Drug stocks were mixed early Tuesday as shares of Abbott Laboratories climbed on a clinical study showing patients who received its new drug-coated stent Xience V suffered fewer cardiac complications that those who received Boston Scientific Corp.'s Taxus stent.
ABT) shares were up 3% at $54.22. Abbott said that a long-term study showed Xience recipients had a 45% lower risk of suffering a major cardiac event and a 32% lower risk of suffering certain blood vessel complications after two years than those who received the Taxus stent.
(
Xience's technology was originally developed by Guidant Corp., which was acquired in 2006 by Boston Scientific. As part of a side deal to that merger, both Boston Scientific and Abbott have the right to market Xience. Boston Scientific has been selling the product under the brand name Promus.
Abbott and Boston Scientific hope to receive U.S. regulatory approval for Xience/Promus during the next few months. The product is already on the market in Europe.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
singaporegal
Supreme |
13-May-2008 21:20
Yells: "Female TA nut" |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Bollinger bands are very tight on this counter. Large price change may occur soon. Other TA charts like Acc/Dist and Chaikin show mixed signals. Some uncertainity from the TA perspective... |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
bengster68
Master |
13-May-2008 19:25
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Xtent and Devax could be close to getting their CE Mark. BIG and Terumo got theirs in mid-Jan 2008. Since the BiolimusA9 and PLA biodegradable polymer now a CE approved DES drug and technology formula, i think CE has much lesser excuse to further delay BIG's other 2 licensees. BIG and group of licensees are going to be the strongest emerging force in DES industry. When i see other DESs got only CE Mark (eg: Medtronic's Endeavor and Abbot's Xience), they claimed that they are selling these DESs in over 100 countries globally. I think CE Mark standards are essentially accepted by almost all countries except in North America. Correct me if Im wrong here. Anyone has info on this? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
A02041315
Senior |
13-May-2008 17:01
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Thank you Bro.PAE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PensionAlterEgo
Member |
13-May-2008 16:56
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Lookout for this.. Should be more +ves for BIG's Biolimus and Biodegradable Polymer.. MENLO PARK, Calif., May 7 --XTENT, Inc. (Nasdaq: XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately following the late-breaking session. In addition, two-year CUSTOM I data, previously presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting last October, has been accepted for publication in the May issue of EuroIntervention. Schedule of XTENT Events for EuroPCR Tuesday, May 13, 2008, 3:30-6:30 p.m. CEST, Room 1 Late-Breaking Clinical Trial: CUSTOM III trial 6-month follow-up results. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
A02041315
Senior |
13-May-2008 16:45
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Akan datang liao!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1 BIG!!!!!!!!!!!!!!!!CHEONG!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!  
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
allright
Senior |
13-May-2008 16:38
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
For all your clowning...you are ok | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
XiaoMaGe888
Senior |
13-May-2008 16:37
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
XiaoMaGe888
Senior |
13-May-2008 15:17
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Bro.33 no need to be worry, accuracy 99.9%
CHIONG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
novena_33
Veteran |
13-May-2008 15:10
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
bro u accuracy or not...? if u r...i dont mind join in the fun...
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
XiaoMaGe888
Senior |
13-May-2008 14:47
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
BIG!!!!!!!!!!!!!!!!!!LAI LIAO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! CHIONG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
